Menu Search
Equities

Exicure Inc

2H0A:DEU

Exicure Inc

Actions
  • Price (EUR)0.286
  • Today's Change-0.006 / -2.05%
  • Shares traded0.00
  • 1 Year change-74.69%
  • Beta--
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is into exploring strategic alternatives to maximize stockholder value. It is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The Company is exploring transactions in industries unrelated to its historical operations. It does not generate any revenues. It wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.

  • Revenue in USD (TTM)500.00k
  • Net income in USD-13.34m
  • Incorporated2017
  • Employees6.00
  • Location
    Exicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
  • Phone+1 (847) 673-1700
  • Fax+1 (847) 556-6411
  • Websitehttps://www.exicuretx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.